

INTERLEUKIN GENETICS INC  
Form 8-K  
October 30, 2009

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported) **October 26, 2009**

**Interleukin Genetics, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**001-32715**

(Commission File Number)

**94-3123681**

(IRS Employer Identification No.)

**135 Beaver Street Waltham, MA**  
(Address of Principal Executive Offices)

**02452**  
(Zip Code)

**(781) 398-0700**

(Registrant's Telephone Number, Including Area Code)

Delaware

## Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT**

On October 26, 2009, Interleukin Genetics, Inc. (the Company) entered into a Merchant Network and Channel Partner Agreement (the Agreement) with Amway Corp. d/b/a Amway Global (Amway Global), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global will sell the Company's Inherent Health brand of genetic tests through its e-commerce Web site via a hyperlink to the Company's e-commerce site. Amway Global will receive a commission equal to a percentage of net sales received by the Company from Amway Global customers. The Agreement has an initial term of 12 months and is automatically renewable for successive 12-month terms. The Agreement may be terminated by either party upon 120 days written notice.

A copy of the Company's press release, dated October 29, 2009, announcing the Company's entry into the Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

(d) Exhibit.

99.1 Press Release dated October 29, 2009.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Interleukin Genetics, Inc.**  
(Registrant)

Date: October 30, 2009

/s/ Eliot Lurier  
Eliot Lurier  
Chief Financial Officer  
(Signature)